Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson’s Disease View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2001-09

AUTHORS

Mahyar Etminan, Ali Samii, Bahi Takkouche, Paula A. Rochon

ABSTRACT

BACKGROUND: Recent case reports and letters have alerted practitioners to the risk of sleep attacks, usually preceded by somnolence, in patients with Parkinson's disease treated with pramipexole and ropinirole. OBJECTIVE: To quantify the risk of somnolence with the new dopamine agonists pramipexole and ropinirole in patients with Parkinson's disease. METHODS: We searched MEDLINE, EMBASE, International Pharmaceutical Abstracts and Cochrane Library, contacted experts and pharmaceutical manufacturers, and manually reviewed all references retrieved to identify possible articles to include. Information on randomisation, blinding, type of treatment and reporting of somnolence were abstracted by 2 independent reviewers. Disagreements were resolved by a third author. ANALYSIS: We made 2 separate analyses. The first analysis compared the risk of somnolence in patients taking either pramipexole or ropinirole to that in patients taking placebo. The second analysis compared the risk of somnolence with these drugs (plus levodopa) versus that with levodopa alone. We calculated pooled relative risk estimates using the random effects model and when no heterogeneity was detected we used the fixed effects model. RESULTS: Four trials were included in the analysis of patients taking pramipexole or ropinirole compared with those taking placebo. The pooled relative risk of somnolence in this analysis was 4.98 [95% confidence interval (CI) 1.79 to 13.89]. Seven trials were included in the analysis of patients taking levodopa and pramipexole or ropinirole compared with those taking levodopa alone. The pooled relative risk was 2.06 (95% CI 1.47 to 2.88). CONCLUSION: Patients with Parkinson's disease using pramipexole or ropinirole are at higher risk of experiencing somnolence relative to patients taking placebo. Patients taking levodopa plus either one of these dopamine agonists are at higher risk than those taking levodopa alone. Clinicians should carefully weigh this risk against the benefit of these agents when prescribing these drugs. More... »

PAGES

863-868

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00002018-200124110-00007

DOI

http://dx.doi.org/10.2165/00002018-200124110-00007

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1023820158

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11665873


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiparkinson Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzothiazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disorders of Excessive Somnolence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dopamine Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Levodopa", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "MEDLINE", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Parkinson Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pramipexole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Toronto", 
          "id": "https://www.grid.ac/institutes/grid.17063.33", 
          "name": [
            "Kunin-Lunenfeld Applied Research Unit, Department of Pharmacy, Baycrest Center for Geriatric Care, 3560 Bathurst Street, M6A 2E1, Toronto, Ontario, Canada", 
            "Department of Clinical Epidemiology, University of Toronto, Toronto, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Etminan", 
        "givenName": "Mahyar", 
        "id": "sg:person.0777312127.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777312127.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington", 
          "id": "https://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "Department of Neurology, School of Medicine, University of Washington, Seattle, Washington, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Samii", 
        "givenName": "Ali", 
        "id": "sg:person.0674274205.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674274205.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Santiago de Compostela", 
          "id": "https://www.grid.ac/institutes/grid.11794.3a", 
          "name": [
            "Department of Preventive Medicine, Faculty of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takkouche", 
        "givenName": "Bahi", 
        "id": "sg:person.01161765574.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161765574.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Toronto", 
          "id": "https://www.grid.ac/institutes/grid.17063.33", 
          "name": [
            "Kunin-Lunenfeld Applied Research Unit, Department of Pharmacy, Baycrest Center for Geriatric Care, 3560 Bathurst Street, M6A 2E1, Toronto, Ontario, Canada", 
            "Departments of Medicine and Public Health Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada", 
            "Institute for Clinical Evaluative Sciences, Sunnybrook and Women\u2019s College Health Sciences Centre, Toronto, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rochon", 
        "givenName": "Paula A.", 
        "id": "sg:person.01005772611.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005772611.81"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(00)02119-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000540305"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(00)02118-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001101689"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mds.870090107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001244206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.284.15.1931", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002894278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1531-8257(200007)15:4<601::aid-mds1003>3.0.co;2-q", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005910454"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.1997.03550020057038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008045474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(05)73981-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025015556"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00002826-199619030-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025122981"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mds.870130111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026535489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mds.870130111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026535489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200005183422004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034176125"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/jnnp.66.4.436", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039149672"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.aje.a009981", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042600360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044748192"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1531-8257(200007)15:4<658::aid-mds1009>3.0.co;2-n", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048708797"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archneur.55.9.1211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054116661"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.278.2.125", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054161656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.49.2.393", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064375188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.49.2.393", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064375188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.49.2.393", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064375188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.49.3.724", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064375305"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.49.3.724", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064375305"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.49.3.724", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064375305"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.51.4.1057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064376768"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.51.4.1057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064376768"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.51.4.1057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064376768"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.52.9.1908", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064377530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.52.9.1908", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064377530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.52.9.1908", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064377530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.53.3.573", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064377675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.53.3.573", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064377675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.53.3.573", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064377675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082880595", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082935991", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083258004", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083274678", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2001-09", 
    "datePublishedReg": "2001-09-01", 
    "description": "BACKGROUND: Recent case reports and letters have alerted practitioners to the risk of sleep attacks, usually preceded by somnolence, in patients with Parkinson's disease treated with pramipexole and ropinirole.\nOBJECTIVE: To quantify the risk of somnolence with the new dopamine agonists pramipexole and ropinirole in patients with Parkinson's disease.\nMETHODS: We searched MEDLINE, EMBASE, International Pharmaceutical Abstracts and Cochrane Library, contacted experts and pharmaceutical manufacturers, and manually reviewed all references retrieved to identify possible articles to include. Information on randomisation, blinding, type of treatment and reporting of somnolence were abstracted by 2 independent reviewers. Disagreements were resolved by a third author.\nANALYSIS: We made 2 separate analyses. The first analysis compared the risk of somnolence in patients taking either pramipexole or ropinirole to that in patients taking placebo. The second analysis compared the risk of somnolence with these drugs (plus levodopa) versus that with levodopa alone. We calculated pooled relative risk estimates using the random effects model and when no heterogeneity was detected we used the fixed effects model.\nRESULTS: Four trials were included in the analysis of patients taking pramipexole or ropinirole compared with those taking placebo. The pooled relative risk of somnolence in this analysis was 4.98 [95% confidence interval (CI) 1.79 to 13.89]. Seven trials were included in the analysis of patients taking levodopa and pramipexole or ropinirole compared with those taking levodopa alone. The pooled relative risk was 2.06 (95% CI 1.47 to 2.88).\nCONCLUSION: Patients with Parkinson's disease using pramipexole or ropinirole are at higher risk of experiencing somnolence relative to patients taking placebo. Patients taking levodopa plus either one of these dopamine agonists are at higher risk than those taking levodopa alone. Clinicians should carefully weigh this risk against the benefit of these agents when prescribing these drugs.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00002018-200124110-00007", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096281", 
        "issn": [
          "0114-5916", 
          "1179-1942"
        ], 
        "name": "Drug Safety", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "name": "Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson\u2019s Disease", 
    "pagination": "863-868", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "717bbf921409405730d801ac11c5854860b117d3da07c50c380c56c140f201ef"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11665873"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9002928"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00002018-200124110-00007"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1023820158"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00002018-200124110-00007", 
      "https://app.dimensions.ai/details/publication/pub.1023820158"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:39", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70046_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00002018-200124110-00007"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00002018-200124110-00007'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00002018-200124110-00007'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00002018-200124110-00007'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00002018-200124110-00007'


 

This table displays all metadata directly associated to this object as RDF triples.

226 TRIPLES      21 PREDICATES      68 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00002018-200124110-00007 schema:about N057a8b06b1a748848a59bd6ab655967f
2 N096f8d46fcf74d9ba4a512df8a709c46
3 N3b610512d810405d869f99846652da9b
4 N408fdb27bcfc4d3aad9bb4069d8b04a6
5 N479578ac6cd0402991957e24e8467b27
6 N56d9b4eac5114cbebd752636959d59e4
7 N72707bdc888e46b798f033ec3aba8494
8 N78feb09d2b3e4fb0b6e66ac0829543ef
9 N802a1bf2df6442e3884f60fe793aec05
10 N8096b00896854812b7fce36b853a603d
11 Nbbdbf191888643339ab039e56c244fa6
12 Ndace4034e4534aa0b8849363eda4aa63
13 Ne143a98d3d2a4a70b159bf0c3c5bb91b
14 Nfc924e9e6dd94bf58006d9d478599512
15 anzsrc-for:11
16 anzsrc-for:1117
17 schema:author Nc140e62ee257421ab805fb27664b30a4
18 schema:citation https://app.dimensions.ai/details/publication/pub.1082880595
19 https://app.dimensions.ai/details/publication/pub.1082935991
20 https://app.dimensions.ai/details/publication/pub.1083258004
21 https://app.dimensions.ai/details/publication/pub.1083274678
22 https://doi.org/10.1001/archneur.55.9.1211
23 https://doi.org/10.1001/jama.1997.03550020057038
24 https://doi.org/10.1001/jama.278.2.125
25 https://doi.org/10.1001/jama.284.15.1931
26 https://doi.org/10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h
27 https://doi.org/10.1002/1531-8257(200007)15:4<601::aid-mds1003>3.0.co;2-q
28 https://doi.org/10.1002/1531-8257(200007)15:4<658::aid-mds1009>3.0.co;2-n
29 https://doi.org/10.1002/mds.870090107
30 https://doi.org/10.1002/mds.870130111
31 https://doi.org/10.1016/s0140-6736(00)02118-8
32 https://doi.org/10.1016/s0140-6736(00)02119-x
33 https://doi.org/10.1016/s0140-6736(05)73981-7
34 https://doi.org/10.1056/nejm200005183422004
35 https://doi.org/10.1093/oxfordjournals.aje.a009981
36 https://doi.org/10.1097/00002826-199619030-00005
37 https://doi.org/10.1136/jnnp.66.4.436
38 https://doi.org/10.1212/wnl.49.2.393
39 https://doi.org/10.1212/wnl.49.3.724
40 https://doi.org/10.1212/wnl.51.4.1057
41 https://doi.org/10.1212/wnl.52.9.1908
42 https://doi.org/10.1212/wnl.53.3.573
43 schema:datePublished 2001-09
44 schema:datePublishedReg 2001-09-01
45 schema:description BACKGROUND: Recent case reports and letters have alerted practitioners to the risk of sleep attacks, usually preceded by somnolence, in patients with Parkinson's disease treated with pramipexole and ropinirole. OBJECTIVE: To quantify the risk of somnolence with the new dopamine agonists pramipexole and ropinirole in patients with Parkinson's disease. METHODS: We searched MEDLINE, EMBASE, International Pharmaceutical Abstracts and Cochrane Library, contacted experts and pharmaceutical manufacturers, and manually reviewed all references retrieved to identify possible articles to include. Information on randomisation, blinding, type of treatment and reporting of somnolence were abstracted by 2 independent reviewers. Disagreements were resolved by a third author. ANALYSIS: We made 2 separate analyses. The first analysis compared the risk of somnolence in patients taking either pramipexole or ropinirole to that in patients taking placebo. The second analysis compared the risk of somnolence with these drugs (plus levodopa) versus that with levodopa alone. We calculated pooled relative risk estimates using the random effects model and when no heterogeneity was detected we used the fixed effects model. RESULTS: Four trials were included in the analysis of patients taking pramipexole or ropinirole compared with those taking placebo. The pooled relative risk of somnolence in this analysis was 4.98 [95% confidence interval (CI) 1.79 to 13.89]. Seven trials were included in the analysis of patients taking levodopa and pramipexole or ropinirole compared with those taking levodopa alone. The pooled relative risk was 2.06 (95% CI 1.47 to 2.88). CONCLUSION: Patients with Parkinson's disease using pramipexole or ropinirole are at higher risk of experiencing somnolence relative to patients taking placebo. Patients taking levodopa plus either one of these dopamine agonists are at higher risk than those taking levodopa alone. Clinicians should carefully weigh this risk against the benefit of these agents when prescribing these drugs.
46 schema:genre research_article
47 schema:inLanguage en
48 schema:isAccessibleForFree false
49 schema:isPartOf N91adc11e47794ba7babce8288dbef110
50 Nef7e096e888e47e78cb066eb5dad74c0
51 sg:journal.1096281
52 schema:name Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson’s Disease
53 schema:pagination 863-868
54 schema:productId N139c9670afd943cfb980b7fc1f96e062
55 N7f27b77e4aad47c49d47187ed76d3244
56 N859e9d5d24064ae39b3be2b6657de5dc
57 N9dfeb06ccfa94937b298bf1753816644
58 Ne39c78905aa04ed29d91e0186ff73b33
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023820158
60 https://doi.org/10.2165/00002018-200124110-00007
61 schema:sdDatePublished 2019-04-11T12:39
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher N2376985e1a4249369814dae2218a1f35
64 schema:url http://link.springer.com/10.2165/00002018-200124110-00007
65 sgo:license sg:explorer/license/
66 sgo:sdDataset articles
67 rdf:type schema:ScholarlyArticle
68 N057a8b06b1a748848a59bd6ab655967f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Pramipexole
70 rdf:type schema:DefinedTerm
71 N096f8d46fcf74d9ba4a512df8a709c46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Thiazoles
73 rdf:type schema:DefinedTerm
74 N139c9670afd943cfb980b7fc1f96e062 schema:name readcube_id
75 schema:value 717bbf921409405730d801ac11c5854860b117d3da07c50c380c56c140f201ef
76 rdf:type schema:PropertyValue
77 N2376985e1a4249369814dae2218a1f35 schema:name Springer Nature - SN SciGraph project
78 rdf:type schema:Organization
79 N3b610512d810405d869f99846652da9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Humans
81 rdf:type schema:DefinedTerm
82 N408fdb27bcfc4d3aad9bb4069d8b04a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Parkinson Disease
84 rdf:type schema:DefinedTerm
85 N479578ac6cd0402991957e24e8467b27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Levodopa
87 rdf:type schema:DefinedTerm
88 N56d9b4eac5114cbebd752636959d59e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Drug Therapy, Combination
90 rdf:type schema:DefinedTerm
91 N64cad5700f64442fa7013db111099e53 rdf:first sg:person.01161765574.42
92 rdf:rest N76c5e8fb7cc94e259e3fdf9ad4875360
93 N72707bdc888e46b798f033ec3aba8494 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Antiparkinson Agents
95 rdf:type schema:DefinedTerm
96 N76c5e8fb7cc94e259e3fdf9ad4875360 rdf:first sg:person.01005772611.81
97 rdf:rest rdf:nil
98 N78feb09d2b3e4fb0b6e66ac0829543ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Benzothiazoles
100 rdf:type schema:DefinedTerm
101 N7f27b77e4aad47c49d47187ed76d3244 schema:name pubmed_id
102 schema:value 11665873
103 rdf:type schema:PropertyValue
104 N802a1bf2df6442e3884f60fe793aec05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Dopamine Agonists
106 rdf:type schema:DefinedTerm
107 N8096b00896854812b7fce36b853a603d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Risk Factors
109 rdf:type schema:DefinedTerm
110 N859e9d5d24064ae39b3be2b6657de5dc schema:name dimensions_id
111 schema:value pub.1023820158
112 rdf:type schema:PropertyValue
113 N91adc11e47794ba7babce8288dbef110 schema:issueNumber 11
114 rdf:type schema:PublicationIssue
115 N9dfeb06ccfa94937b298bf1753816644 schema:name doi
116 schema:value 10.2165/00002018-200124110-00007
117 rdf:type schema:PropertyValue
118 Nbbdbf191888643339ab039e56c244fa6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Randomized Controlled Trials as Topic
120 rdf:type schema:DefinedTerm
121 Nc140e62ee257421ab805fb27664b30a4 rdf:first sg:person.0777312127.85
122 rdf:rest Nd03ef7ee7ef24fd28191f74f27481276
123 Nd03ef7ee7ef24fd28191f74f27481276 rdf:first sg:person.0674274205.79
124 rdf:rest N64cad5700f64442fa7013db111099e53
125 Ndace4034e4534aa0b8849363eda4aa63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Disorders of Excessive Somnolence
127 rdf:type schema:DefinedTerm
128 Ne143a98d3d2a4a70b159bf0c3c5bb91b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Indoles
130 rdf:type schema:DefinedTerm
131 Ne39c78905aa04ed29d91e0186ff73b33 schema:name nlm_unique_id
132 schema:value 9002928
133 rdf:type schema:PropertyValue
134 Nef7e096e888e47e78cb066eb5dad74c0 schema:volumeNumber 24
135 rdf:type schema:PublicationVolume
136 Nfc924e9e6dd94bf58006d9d478599512 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name MEDLINE
138 rdf:type schema:DefinedTerm
139 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
140 schema:name Medical and Health Sciences
141 rdf:type schema:DefinedTerm
142 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
143 schema:name Public Health and Health Services
144 rdf:type schema:DefinedTerm
145 sg:journal.1096281 schema:issn 0114-5916
146 1179-1942
147 schema:name Drug Safety
148 rdf:type schema:Periodical
149 sg:person.01005772611.81 schema:affiliation https://www.grid.ac/institutes/grid.17063.33
150 schema:familyName Rochon
151 schema:givenName Paula A.
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005772611.81
153 rdf:type schema:Person
154 sg:person.01161765574.42 schema:affiliation https://www.grid.ac/institutes/grid.11794.3a
155 schema:familyName Takkouche
156 schema:givenName Bahi
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161765574.42
158 rdf:type schema:Person
159 sg:person.0674274205.79 schema:affiliation https://www.grid.ac/institutes/grid.34477.33
160 schema:familyName Samii
161 schema:givenName Ali
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674274205.79
163 rdf:type schema:Person
164 sg:person.0777312127.85 schema:affiliation https://www.grid.ac/institutes/grid.17063.33
165 schema:familyName Etminan
166 schema:givenName Mahyar
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777312127.85
168 rdf:type schema:Person
169 https://app.dimensions.ai/details/publication/pub.1082880595 schema:CreativeWork
170 https://app.dimensions.ai/details/publication/pub.1082935991 schema:CreativeWork
171 https://app.dimensions.ai/details/publication/pub.1083258004 schema:CreativeWork
172 https://app.dimensions.ai/details/publication/pub.1083274678 schema:CreativeWork
173 https://doi.org/10.1001/archneur.55.9.1211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054116661
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1001/jama.1997.03550020057038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008045474
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1001/jama.278.2.125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054161656
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1001/jama.284.15.1931 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002894278
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h schema:sameAs https://app.dimensions.ai/details/publication/pub.1044748192
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1002/1531-8257(200007)15:4<601::aid-mds1003>3.0.co;2-q schema:sameAs https://app.dimensions.ai/details/publication/pub.1005910454
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1002/1531-8257(200007)15:4<658::aid-mds1009>3.0.co;2-n schema:sameAs https://app.dimensions.ai/details/publication/pub.1048708797
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1002/mds.870090107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001244206
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1002/mds.870130111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026535489
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/s0140-6736(00)02118-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001101689
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/s0140-6736(00)02119-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1000540305
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/s0140-6736(05)73981-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025015556
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1056/nejm200005183422004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034176125
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1093/oxfordjournals.aje.a009981 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042600360
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1097/00002826-199619030-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025122981
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1136/jnnp.66.4.436 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039149672
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1212/wnl.49.2.393 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064375188
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1212/wnl.49.3.724 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064375305
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1212/wnl.51.4.1057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064376768
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1212/wnl.52.9.1908 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064377530
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1212/wnl.53.3.573 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064377675
214 rdf:type schema:CreativeWork
215 https://www.grid.ac/institutes/grid.11794.3a schema:alternateName University of Santiago de Compostela
216 schema:name Department of Preventive Medicine, Faculty of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
217 rdf:type schema:Organization
218 https://www.grid.ac/institutes/grid.17063.33 schema:alternateName University of Toronto
219 schema:name Department of Clinical Epidemiology, University of Toronto, Toronto, Ontario, Canada
220 Departments of Medicine and Public Health Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
221 Institute for Clinical Evaluative Sciences, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada
222 Kunin-Lunenfeld Applied Research Unit, Department of Pharmacy, Baycrest Center for Geriatric Care, 3560 Bathurst Street, M6A 2E1, Toronto, Ontario, Canada
223 rdf:type schema:Organization
224 https://www.grid.ac/institutes/grid.34477.33 schema:alternateName University of Washington
225 schema:name Department of Neurology, School of Medicine, University of Washington, Seattle, Washington, USA
226 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...